Notify Therapeutics

Notify Therapeutics is a preclinical-stage biotech targeting a significant unmet need in fertility: women with low ovarian reserve who do not respond to standard hormonal stimulation. The company's novel, non-hormonal therapy acts on the early stages of follicle development and has shown proof-of-concept efficacy in rodent models and ex-vivo patient samples. If successful, this approach could offer a new treatment paradigm for a large patient population currently with limited options, potentially improving IVF outcomes while reducing risks like multiple pregnancies.

A non-hormonal platform targeting the initial, hormone-independent phase of ovarian follicle development to stimulate egg production in women with low ovarian reserve.

Notify operates in a niche with limited direct competition, as current standard of care (hormonal stimulation) fails its target population. Indirect competitors include companies developing adjuvants for IVF (like androgens or growth hormones) and research into more experimental approaches like in vitro activation (IVA) or mitochondrial replacement. Its main competitive edge is its first-in-class, non-hormonal mechanism.